AVDL Dividend: Avadel Pharmaceuticals PLC Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

AVDL Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	248	169	27	0	0	22
Revenue Growth (YoY)	80%	526%	--	--	-100%	-63%
Cost of Revenue	22	15	0	--	0	5
Gross Profit	226	153	27	--	0	16
Selling, General & Admin	191	181	151	74	68	32
Research & Development	39	15	13	20	17	20
Operating Expenses	231	196	164	95	85	56
Other Non Operating Income (Expenses)	1	4	0	0	2	2
Pretax Income	-3	-49	-160	-111	-93	-5
Income Tax Expense	-2	0	0	26	-15	-2
Net Income	0	-48	-160	-137	-77	7
Net Income Growth	-100%	-70%	17%	78%	-1,200%	-121%
Shares Outstanding (Diluted)	101.27	95.14	80.17	60.09	58.53	54.94
Shares Change (YoY)	5%	19%	33%	3%	7%	47%
EPS (Diluted)	0	-0.51	-2	-2.29	-1.32	0.12
EPS Growth	-99%	-74%	-13%	73%	-1,200%	-112.99%
Free Cash Flow	19	-46	-128	-71	-77	-48
Free Cash Flow Per Share	0.18	-0.48	-1.59	-1.18	-1.31	-0.87
Gross Margin	91.12%	90.53%	100%	--	0%	72.72%
Operating Margin	-1.61%	-24.85%	-507.4%	0%	0%	-177.27%
Profit Margin	0%	-28.4%	-592.59%	0%	0%	31.81%
Free Cash Flow Margin	7.66%	-27.21%	-474.07%	0%	0%	-218.18%
EBITDA	-1	-40	-136	-94	-85	-39
EBITDA Margin	-0.4%	-23.66%	-503.7%	0%	0%	-177.27%
D&A For EBITDA	3	2	1	1	0	0
EBIT	-4	-42	-137	-95	-85	-39
EBIT Margin	-1.61%	-24.85%	-507.4%	0%	0%	-177.27%
Effective Tax Rate	66.66%	0%	0%	-23.42%	16.12%	40%